C07D 473 - Heterocyclic compounds containing purine ring systems

Patents for C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
12/2002
12/27/2002	CA2450934A1 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002	CA2450724A1 Quinazoline and pyrido¬2,3-d\|pyrimidine inhibitors of phosphodiesterase (pde) 7
12/26/2002	US20020198205 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
12/26/2002	US20020198171 Administering to a hepatitis B infection patient an effective treatment amount of a 2'fluoro- beta -D-nucleoside or salts(containing purine or pyrimidine base)
12/26/2002	US20020198170 Formulations of adenosine a1 agonists
12/26/2002	US20020197381 Caffeine complexes with enhanced taste, process for their preparation and their use
12/25/2002	CN1097049C Processes for preparing intermediate product used in method of diastereoselective synthesis of nucleosides
12/24/2002	US6498185 Enzyme factor xa inhibitors
12/24/2002	US6498165 Pyrimidine compounds; prophylaxis and treatment of such as immune diseases, hyperproliferative disorders, cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis, psoriasis
12/19/2002	WO2002083651A3 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
12/19/2002	US20020193410 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
12/19/2002	US20020193353 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
12/18/2002	EP1265899A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/18/2002	EP1265890A1 Stereoselective synthesis of nucleoside analogues
12/18/2002	EP1265861A2 Benzylated pde4 inhibitors
12/18/2002	EP0885224B1 Process for preparing ganciclovir derivatives
12/18/2002	CN1096461C Purine derivatives and their use as anti-coagulants
12/17/2002	US6495687 Adenosine receptors are involved in a vast number of peripheral and central regulatory mechanisms such as, for example, vasodilation, cardiac depression, inhibition of lipolysis, inhibition of insulin release and potentiation
12/17/2002	US6495555 Tricyclic Δ-3-piperidines as α2-antagonists
12/17/2002	CA2203389C Bicyclic heterocyclic compounds for the treatment of impotence
12/17/2002	CA2053826C Pharmaceutical compositions active in the therapy of neurological affections in aids patients
12/12/2002	WO2002098878A1 Trifluoromethylpurines as phosphodiesterase 4 inhibitors
12/12/2002	WO2002004450A3 Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
12/12/2002	WO2001054731A3 Ligand conjugates and methods for preparing same
12/12/2002	US20020188125 Viricides such as (R)-9-(2-(stearoyloxymethyl)-4-(L-valyloxy) butyl)guanine for treatment of HIV; bioavailability
12/12/2002	CA2438099A1 Trifluoromethylpurines as phosphodiesterase 4 inhibitors
12/11/2002	EP1263732A1 Corticotropin releasing factor antagonists
12/11/2002	EP0793498B1 Bicyclic heterocyclic compounds for the treatment of impotence
12/11/2002	EP0662958B1 1-(2-oxo-acetyl)-piperidine-2-carboxylic acid derivatives as multi-drug-resistent cancer cell sensitizers
12/11/2002	CN1384833A Synthesis and methods of use of 9-substituted guanine derivatives
12/11/2002	CN1095842C Prep. of cyclopropane derivatives with anti-virus effectiveness and intermediate therefor
12/10/2002	US6492348 Adenosine derivatives
12/05/2002	US20020179540 Filtration; countercurrent sweeping of filter; trapping particles during expansion of flux
12/04/2002	EP0907650B1 N- 4-(heteroarylmethyl)phenyl]-heteroarylamines
12/03/2002	US6489338 Imidazopyridine and imidazopyrimidine antiviral agents
12/03/2002	US6489333 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
12/03/2002	US6489332 A1 adenosine receptor antagonists
12/03/2002	US6489330 Or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of such as famciclovir; prophylactic treatment for kaposi's sarcoma or aids related disease
12/03/2002	CA2263500C Malonate derivatives useful as intermediates for producing isoxazolidinadione hypoglycemic agents
11/2002
11/28/2002	WO2002094740A2 Hydrogenation processes performed in ionic liquids
11/28/2002	US20020177609 Fatty alcohol drug conjugates
11/28/2002	CA2446835A1 Hydrogenation processes performed in ionic liquids
11/27/2002	EP0998480B1 Nucleotide analog composition and synthesis method
11/27/2002	EP0915093B1 Amide derivatives
11/27/2002	EP0776331B1 Higher order structure and binding of peptide nucleic acids
11/26/2002	US6486187 N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
11/21/2002	WO2002092093A1 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
11/21/2002	WO2002091988A2 Novel processes for the preparation of adenosine compounds and intermediates thereto
11/21/2002	US20020173649 Chloropvrimidine intermediates
11/21/2002	US20020173648 Use in the treatment of PDE4 and TNF mediated diseases
11/21/2002	CA2447408A1 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
11/21/2002	CA2446605A1 Novel processes for the preparation of adenosine compounds and intermediates thereto
11/20/2002	EP1258247A1 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
11/20/2002	EP1257555A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
11/20/2002	EP1257552A1 Xanthine derivatives, intermediates and use for treating osteoporosis
11/20/2002	EP0892780B1 M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS
11/19/2002	US6482957 Useful as an intermediate of a carbocyclic nucleoside anti-viral agent; reacting 2-azabicyclo(2.2.1)hept-5-en-3-one with a sulfonyl halide or phosphoryl halide and then with a nucleic acid base
11/14/2002	WO2002090358A1 Disubstituted 7,9-guaninium halides as telomerase inhibitors
11/14/2002	WO2002090357A1 Disubstituted 1,7-guanines
11/14/2002	WO2002090314A1 Pyruvate derivatives
11/14/2002	WO2001097787A3 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
11/14/2002	US20020169174 Xanthine phosphodiesterase V inhibitors
11/13/2002	EP1256574A1 Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
11/13/2002	EP1255764A1 Purine derivatives
11/12/2002	US6479673 Antiretroviral enantiomeric nucleotide analogs
11/12/2002	US6479487 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
11/07/2002	WO2002088080A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088079A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	US20020165365 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same
11/07/2002	US20020165242 Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
11/07/2002	US20020165241 Such as 4-((methyl-pyrimidin-2-ylamino)-methyl)-piperidine-1-carboxylic acid benzyl ester; useful for pain relief; treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, and stroke; N-methyl-D-aspartate (NMDA)
11/07/2002	US20020165202 Antiinflammatory agents; antiproliferative agents
11/07/2002	US20020165197 Administering adenosine receptor ligand
11/07/2002	CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002	CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/06/2002	EP1253924A1 Nitrate salts of antimicrobial agents
11/06/2002	EP0971923B1 Synthesis of acyclic nucleoside derivatives
11/06/2002	CN1378551A 嘌呤衍生物 Purine derivatives
11/05/2002	US6476041 1,4 substituted piperidinyl NMDA/NR2B antagonists
11/05/2002	US6476040 Processes and intermediates for preparing anti-cancer compounds
10/2002
10/31/2002	WO2002085905A1 Novel adenine derivatives
10/31/2002	WO2002085904A1 Snythesis and methods of use of purine analogues and derivatives
10/31/2002	WO2002085838A1 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
10/31/2002	WO2002085413A1 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same
10/31/2002	US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002	US20020161001 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
10/30/2002	EP1252160A1 Methanocarba cycloalkyl nucleoside analogues
10/30/2002	CN1377356A Certain alkylene diamine-substituted heterocycles
10/30/2002	CN1377353A Purine derivatives having phosphodiesterase IN inhibition activity
10/30/2002	CN1377352A Selective antagonists of A28 adenosine receptors
10/30/2002	CN1377347A 药学活性磺酰胺衍生物 Pharmaceutically active sulfonamide derivatives
10/24/2002	WO2002083651A2 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	US20020156277 Stimulating nerve growth or regeneration to treat central nervous system disorders
10/24/2002	DE10117803A1 New 8-substituted-xanthine derivatives, useful e.g. for treating diabetes and arthritis, act by inhibiting dipeptidylpeptidase-IV
10/24/2002	CA2444148A1 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
10/23/2002	EP1250315A1 Functional monomers for molecular recognition and catalysis
10/23/2002	EP1196384A4 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
10/22/2002	US6469017 Method of inhibiting interleukin-12 signaling

1 ... 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 ... 120